Viatris Inc. (NASDAQ: VTRS): Viatris Inc. (“Viatris” or the “Company”) and certain of the Company’s senior executives have been sued for violations of the federal securities laws. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Viatris securities. The case is pending in the U.S. District Court for the Western District of Pennsylvania and is captioned Quinn v. Viatris Inc., et al., No. 25-cv-466.
 
If you incurred losses on your investments in Viatris, you are encouraged to submit your information.
 
Why was Viatris Sued for Securities Fraud?
 
Viatris is a global healthcare company that supplies medicines to about 1 billion patients across more than 165 countries and territories. The complaint alleges that Viatris stated its facilities were in “good operating condition,” were “suitable for their intended purposes,” and that the Company was “committed to maintaining the highest quality manufacturing standards.”
 
However, on December 23, 2024, the Company revealed that the U.S. Food and Drug Administration had issued a Warning Letter following a failed inspection at the Company’s Indore, India, facility. Still, Viatris downplayed the situation, describing it as a “little bit of headwind” and spoke about “active discussions with the FDA” to get additional products produced at the facility exempted from the FDA’s Import Alert.
 
In truth, the ramifications of the failed FDA inspection resulted in a significant headwind to the Company’s financial results as it prevented the Company from manufacturing and distributing key products, including Lenalidomide.
 
The Stock Declines as the Truth is Revealed
 
On February 27, 2025, the Company released its Q4 2024 results and provided 2025 guidance. The Company revealed that the “negative impact” of the Indore facility’s failed inspection would lower 2025 revenue by “approximately $500 million” and 2025 earnings from operations by “approximately $385 million.” The Company further disclosed that the failed inspection at its Indore facility prevented it from identifying alternative supply options for Lenalidomide and from obtaining further product exemptions from the FDA. On this news, the price of Viatris stock declined roughly 15% during the trading day, from a closing price of $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025.
 
What are my Rights?
 
If you purchased or otherwise acquired Viatris securities, you may ask the Court no later than June 3, 2025, which is the first business day after 60 days from the date of the publication of notice of pendency of the action, to appoint you as Lead Plaintiff through counsel of your choice. To be a member of the Class, you need not take any action at this time. The ability to share in any potential future recovery is not dependent on serving as Lead Plaintiff.
 
If you incurred losses on your investments in Viatris, you are encouraged to submit your information to speak with an attorney about your rights.
 
You can also contact:
Ross Shikowitz
ross@bfalaw.com
212-789-3619
 
All representation is on a contingency fee basis. Shareholders are not responsible for any court costs or expenses of litigation. The Firm will seek court approval for any potential fees and expenses.
 
Why Bleichmar Fonti & Auld LLP?
 
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
 
Attorney advertising. Past results do not guarantee future outcomes.